Research programme: DNA damage response targeting anticancer therapeutics - DeepCure
Latest Information Update: 23 Mar 2023
Price :
$50 *
At a glance
- Originator DeepCure
- Class Antineoplastics; Small molecules
- Mechanism of Action DNA damage modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Ovarian cancer; Pancreatic cancer
Most Recent Events
- 23 Mar 2023 Discontinued for Ovarian cancer in USA (unspecified route) before March 2023 (DeepCure Pipeline, March 2023)
- 23 Mar 2023 Discontinued for Pancreatic cancer in USA (unspecified route) before March 2023 (DeepCure Pipeline, March 2023)
- 08 Nov 2021 Early research in Ovarian cancer in USA (unspecified route) (DeepCure pipeline, November 2021)